| Document |
Document Title |
|
WO/2020/169042A1 |
Specifically, the present invention relates to the 6-oxo-1,6-dihydropyridazine prodrug derivative shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, a use thereof as a NaV...
|
|
WO/2020/164970A1 |
The present invention relates to herbicidally active cinnolinium derivatives of formula (I), as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions...
|
|
WO/2020/163541A1 |
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
|
|
WO/2020/163647A1 |
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
|
|
WO/2020/163375A1 |
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
|
|
WO/2020/161248A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
|
|
WO/2020/160151A1 |
A compound having one of formula (1), formula (2), formula (3) and formula (4) or a pharmacologically acceptable salt thereof.
|
|
WO/2020/156571A1 |
Provided is a pyridazine derivative as shown in formula (I), and a use thereof in preparing a drug for the prevention and/or treatment of indications related to HIF modulation. The pyridazine derivative is an ideal, highly-effective HIF-...
|
|
WO/2020/159904A1 |
Compounds having the following formula (I): (Formula (I)) or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.
|
|
WO/2020/157199A1 |
The present invention includes name compounds of general formula (I) : (I), in which R1, R2, R3 and A are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical ...
|
|
WO/2020/140959A1 |
A 6-oxo-1,6-dihydropyridazine derivative, a preparation method therefor and medical use thereof, in particular, a 6-oxo-1,6-dihydropyridazine derivative represented by general formula (I), a preparation method therefor, and a pharmaceuti...
|
|
WO/2020/127168A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
|
|
WO/2020/127780A1 |
The present disclosure relates to heterocyclyl pyridazine compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.
|
|
WO/2020/122092A1 |
The present invention provides a heterocyclic compound having orexin receptor type 2 agonist activity. A compound represented by formula (I) [in the formula, each symbol is as described in the description] or a salt thereof has orexin ...
|
|
WO/2020/115548A1 |
Combination therapies comprising administering radioimmunoconjugates and DNA damage response inhibitors.
|
|
WO/2020/114869A1 |
The present invention relates to the use of herbicidal substituted phenyl-pyridazinediones and substituted phenyl-pyridazinone derivatives of formula (I), in combination with herbicidal pyrrolidinone derivatives of the formula (II) to co...
|
|
WO/2020/109039A1 |
The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description formula ...
|
|
WO/2020/109391A1 |
The present disclosure relates to pyridazine (thio)amide compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.
|
|
WO/2020/102572A1 |
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. Furthermore, the subject compounds and compositions are ...
|
|
WO/2020/099367A1 |
Use of the compounds of the formula (I) wherein the substituents are as defined herein as herbicides. Compounds of formula (I) are also claimed.
|
|
WO/2020/097258A1 |
Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, amon...
|
|
WO/2020/093272A1 |
The present application belongs to the technical field of organic chemistry, and particularly relates to a sulfonyl fluoride-containing compound with high affinity to a PARP receptor, or a pharmaceutically acceptable salt, isomer, prodru...
|
|
WO/2020/097265A1 |
Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, amon...
|
|
WO/2020/089098A1 |
The present invention relates to novel pyridazines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated...
|
|
WO/2020/081971A1 |
The present disclosure provides a method for treating a cancer or refractory caner and/or inhibiting cancer metastasis, recurrence or progression in a subject or increasing the likelihood of survival over a relevant period in a subject d...
|
|
WO/2020/076123A1 |
The present invention relates to a compound, a photoresist composition comprising same, a photoresist pattern comprising same, and a method for manufacturing a photoresist pattern.
|
|
WO/2020/069056A1 |
Disclosed is a compound of Formula I, including N-oxides, and salts thereof, wherein R1, R2 and R3 are defined as set forth in the disclosure. Also disclosed is a process for preparing a compound of Formula I. A compound of Formula I can...
|
|
WO/2020/069418A1 |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazi...
|
|
WO/2020/069057A1 |
Disclosed are compounds of Formula I and N-oxides or salts thereof, wherein R1 is C1-C4alkyl or C3-C6cycloalkyl; R2 is H, Cl, Br or I; R3 is Cl or OR4; R4 is H or C1-C4 alkyl; R5 is H, F, Cl or CH3; and R6 is H or Cl. Also disclosed is a...
|
|
WO/2020/069402A1 |
Cinnoline compounds of formula (I), variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also desc...
|
|
WO/2020/061473A1 |
Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with a mutation in a protein. One aspect of the invention provides compounds, compositions, and methods useful for trea...
|
|
WO/2020/057391A1 |
Provided is a pyridazinyl amine compound with broad-spectrum herbicidal activity and having a structure represented by general formula (I). The definition of each substituent in the formula is described in the description. The compound h...
|
|
WO/2020/061476A1 |
Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with mutation in a protein. One aspect of the invention provides compounds, compositions, and methods useful for treati...
|
|
WO/2020/051099A1 |
The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as...
|
|
WO/2020/051207A2 |
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...
|
|
WO/2020/047651A1 |
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and poly-(ADP-ribose) polymerase (PARP) inhibitor. The CD47 blocking agent can be SIRPαFc and the PARP inhibitor niraparib. The anti-cancer ...
|
|
WO/2020/041180A1 |
A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives. The one or more solubilizing and/or stabilizing agents may be a cyclodextrin or ...
|
|
WO/2020/038405A1 |
Provided are a preparation method of pyrrolo-amino-pyridazinone compound and an intermediate thereof. The reaction conditions are easy to control, the processing following the reaction is simple, the production rate is high, and the meth...
|
|
WO/2020/022470A1 |
The present invention provide a compound which has excellent ATX inhibitory activity and is thus useful for prophylaxis or treatment of diseases associated with ATX. A carboxylic acid compound which is represented by general formula (1) ...
|
|
WO/2020/017587A1 |
Provided are: a pyridazinone derivative and/or a pharmaceutically acceptable salt thereof, which is useful as a therapeutic agent and/or a prophylactic agent for diseases in which Nav1.1 is involved and various central nervous system dis...
|
|
WO/2020/014243A1 |
Pyridazine compounds for inhibiting NaV1.8 and methods for treating a condition, disease, or disorder associated with an increased NaV1.8 activity or expression are disclosed.
|
|
WO/2020/003298A1 |
The present invention is directed to a polymer comprising a first hyaluronic acid (HA) chain and a second HA chain crosslinked via a linker comprising an unsaturated moiety or a derivative thereof coupled to a tetrazine moiety or a deriv...
|
|
WO/2019/233209A1 |
A catalyst and a method for preparing S-indoxacarb using the catalyst. The catalyst is prepared using 3-tert-butyl-5-chloromethyl salicylaldehyde and cyclohexanediamine as raw materials, where an original quinine catalyst such as cinchon...
|
|
WO/2019/236625A1 |
Disclosed are compounds that activate excitatory amino acid transporter 2 (EAAT2), as well as methods of using these compounds to treat or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.
|
|
WO/2019/236879A1 |
The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing neurodegenerative disease or axonal degeneration. The provided SARM1 inhibitors may reduce or inhibit binding of NAD+ by ...
|
|
WO/2019/237076A1 |
Provided herein are methods, compositions, and kits for inhibiting NMD of mRNA transcribed from a gene comprising one or more nonsense mutations and for treating conditions associated with the presence of said one or more nonsense mutati...
|
|
WO/2019/226820A1 |
Disclosed herein are GABAA positive allosteric modulators for the treatment of pruritic conditions and dermatitis. Also disclosed herein are formulations comprising the GABAA positive allosteric modulators.
|
|
WO/2019/202607A1 |
The present invention relates to a compound of formula I, wherein R is selected from the group consisting of -H, -F, -Cl, -Br, -I, -NO2, -CH3, and -C2H5; X is selected from the group consisting of -F, -Cl, -Br, and –I; and pharmaceutic...
|
|
WO/2019/200120A1 |
The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.
|
|
WO/2019/185932A1 |
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises...
|
